Bioplus Life Sciences is a biopharmaceutical company focused on the discovery and development of drugs targeting myopia. It is engaged in research and development activities.

Bioplus Life Sciences

EmendoBio is involved in developing CRISPR-based gene editing technologies to address complex genetic diseases, focusing on optimizing nucleases and guide-RNAs for effective disease-specific solutions.

EmendoBio

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Metric
Company Name	Bioplus Life Sciences	EmendoBio	WuXi AppTec Co., Ltd.
Symbol			603.26K
MSH ID	IN:BIOPLUS	COM:EMENDOBIO	COM:WUXIAPPTEC
Market	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Biopharmaceuticals	Biotechnology	Medical - Diagnostics & Research
Country	IN	US	CN
Stage
Employee Count			41.12K
Website	bioplus.in	emendobio.com	wuxiapptec.com
LinkedIn
Founders

Metric
Market Cap			14.85B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			5.53B
Revenue (LTM)
Revenue (NTM)
Gross Profit			2.21B
EBITDA			1.86B
Operating Income			1.52B
Net Income			1.33B
EPS			0.45
Diluted EPS			0.45
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.41
Operating Profit Margin			0.31
EBITDA Margin			0.34
Net Profit Margin			0.24
Return on Equity			0.19
Return on Assets			0.13
Return on Capital Employed			0.21

IN:BIOPLUS

Bioplus Life Sciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			14.91
P/B Ratio			2.75
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			6.71
EV Multiple			21.72

Metric
Days Sales Outstanding			83.19
Days Payables Outstanding			33.25
Days Inventory Outstanding			82.65
Operating Cycle			177.98
Cash Conversion Cycle			146.69
Asset Turnover			0.54

Metric
Operating Cash Flow			1.87B
Free Cash Flow			1.11B
Cash Flow to Debt			2.71
Operating Cash Flow/Sales			0.33
Free Cash Flow Yield			0.03

Metric
Cash & Equivalents			1.38B
Accounts Receivable			-295.72M
Inventory			654.30M
Goodwill			251.55M
Debt to Capitalization			0.11
Debt to Assets			0.09
Current Ratio			1.75
Quick Ratio			1.95

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue			0.04
SG&A to Revenue			0.02